vs
JBT Marel Corp（JBTM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
JBT Marel Corp的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs 5.3%，领先7.5%），JBT Marel Corp同比增速更快（115.6% vs 5.9%），Revvity自由现金流更多（$161.8M vs $83.5M），过去两年JBT Marel Corp的营收复合增速更高（60.3% vs 9.0%）
JBT Marel Corp（原称JBT公司、约翰宾技术公司）是主营食品加工机械及自动化车辆的企业，2008年由FMC技术公司拆分非能源业务独立注册成立，总部位于美国伊利诺伊州芝加哥，发展历史可追溯至1884年加州洛斯加托斯果园主约翰·宾创办的企业。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
JBTM vs RVTY — 直观对比
营收规模更大
JBTM
是对方的1.3倍
$772.1M
营收增速更快
JBTM
高出109.7%
5.9%
净利率更高
RVTY
高出7.5%
5.3%
自由现金流更多
RVTY
多$78.3M
$83.5M
两年增速更快
JBTM
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $53.1M | $98.4M |
| 毛利率 | 34.5% | — |
| 营业利润率 | 7.2% | 14.5% |
| 净利率 | 5.3% | 12.7% |
| 营收同比 | 115.6% | 5.9% |
| 净利润同比 | 858.6% | 3.9% |
| 每股收益（稀释后） | $1.04 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JBTMRVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $934.8M | $720.3M | ||
| Q1 25 | $854.1M | $664.8M | ||
| Q4 24 | $467.6M | $729.4M | ||
| Q3 24 | $453.8M | $684.0M | ||
| Q2 24 | $402.3M | $691.7M | ||
| Q1 24 | $392.3M | $649.9M |
净利润JBTMRVTY
| Q4 25 | $53.1M | $98.4M | ||
| Q3 25 | $66.0M | $46.7M | ||
| Q2 25 | $3.4M | $53.9M | ||
| Q1 25 | $-173.0M | $42.2M | ||
| Q4 24 | $-7.0M | $94.6M | ||
| Q3 24 | $38.9M | $94.4M | ||
| Q2 24 | $30.7M | $55.4M | ||
| Q1 24 | $22.8M | $26.0M |
毛利率JBTMRVTY
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.9% | 53.6% | ||
| Q2 25 | 35.8% | 54.5% | ||
| Q1 25 | 34.2% | 56.5% | ||
| Q4 24 | 38.4% | — | ||
| Q3 24 | 36.1% | 56.3% | ||
| Q2 24 | 35.6% | 55.7% | ||
| Q1 24 | 35.8% | 54.6% |
营业利润率JBTMRVTY
| Q4 25 | 7.2% | 14.5% | ||
| Q3 25 | 10.2% | 11.7% | ||
| Q2 25 | 5.2% | 12.6% | ||
| Q1 25 | -3.9% | 10.9% | ||
| Q4 24 | 3.4% | 16.3% | ||
| Q3 24 | 10.3% | 14.3% | ||
| Q2 24 | 6.7% | 12.4% | ||
| Q1 24 | 7.4% | 6.8% |
净利率JBTMRVTY
| Q4 25 | 5.3% | 12.7% | ||
| Q3 25 | 6.6% | 6.7% | ||
| Q2 25 | 0.4% | 7.5% | ||
| Q1 25 | -20.3% | 6.4% | ||
| Q4 24 | -1.5% | 13.0% | ||
| Q3 24 | 8.6% | 13.8% | ||
| Q2 24 | 7.6% | 8.0% | ||
| Q1 24 | 5.8% | 4.0% |
每股收益（稀释后）JBTMRVTY
| Q4 25 | $1.04 | $0.86 | ||
| Q3 25 | $1.26 | $0.40 | ||
| Q2 25 | $0.07 | $0.46 | ||
| Q1 25 | $-3.35 | $0.35 | ||
| Q4 24 | $-0.22 | $0.77 | ||
| Q3 24 | $1.21 | $0.77 | ||
| Q2 24 | $0.95 | $0.45 | ||
| Q1 24 | $0.71 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $919.9M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $4.5B | $7.3B |
| 总资产 | $8.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资JBTMRVTY
| Q4 25 | $167.9M | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务JBTMRVTY
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $648.3M | — | ||
| Q2 24 | $647.7M | — | ||
| Q1 24 | $647.0M | — |
股东权益JBTMRVTY
| Q4 25 | $4.5B | $7.3B | ||
| Q3 25 | $4.4B | $7.4B | ||
| Q2 25 | $4.4B | $7.6B | ||
| Q1 25 | $4.1B | $7.6B | ||
| Q4 24 | $1.5B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.5B | $7.9B | ||
| Q1 24 | $1.5B | $7.8B |
总资产JBTMRVTY
| Q4 25 | $8.2B | $12.2B | ||
| Q3 25 | $8.2B | $12.1B | ||
| Q2 25 | $8.3B | $12.4B | ||
| Q1 25 | $8.0B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
负债/权益比JBTMRVTY
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.34× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.41× | — | ||
| Q2 24 | 0.43× | — | ||
| Q1 24 | 0.43× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $83.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.3% | 21.0% |
| 资本支出强度资本支出/营收 | 3.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.21× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $238.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流JBTMRVTY
| Q4 25 | $117.4M | $182.0M | ||
| Q3 25 | $87.7M | $138.5M | ||
| Q2 25 | $102.2M | $134.3M | ||
| Q1 25 | $34.4M | $128.2M | ||
| Q4 24 | $128.7M | $174.2M | ||
| Q3 24 | $71.9M | $147.9M | ||
| Q2 24 | $21.6M | $158.6M | ||
| Q1 24 | $10.4M | $147.6M |
自由现金流JBTMRVTY
| Q4 25 | $83.5M | $161.8M | ||
| Q3 25 | $56.5M | $120.0M | ||
| Q2 25 | $83.7M | $115.5M | ||
| Q1 25 | $14.4M | $112.2M | ||
| Q4 24 | $118.7M | $149.8M | ||
| Q3 24 | $65.0M | $125.6M | ||
| Q2 24 | $11.1M | $136.6M | ||
| Q1 24 | $-100.0K | $129.7M |
自由现金流率JBTMRVTY
| Q4 25 | 8.3% | 21.0% | ||
| Q3 25 | 5.6% | 17.2% | ||
| Q2 25 | 9.0% | 16.0% | ||
| Q1 25 | 1.7% | 16.9% | ||
| Q4 24 | 25.4% | 20.5% | ||
| Q3 24 | 14.3% | 18.4% | ||
| Q2 24 | 2.8% | 19.7% | ||
| Q1 24 | -0.0% | 20.0% |
资本支出强度JBTMRVTY
| Q4 25 | 3.4% | 2.6% | ||
| Q3 25 | 3.1% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 2.3% | 2.4% | ||
| Q4 24 | 2.1% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 2.6% | 3.2% | ||
| Q1 24 | 2.7% | 2.7% |
现金转化率JBTMRVTY
| Q4 25 | 2.21× | 1.85× | ||
| Q3 25 | 1.33× | 2.97× | ||
| Q2 25 | 30.06× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.85× | 1.57× | ||
| Q2 24 | 0.70× | 2.87× | ||
| Q1 24 | 0.46× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JBTM
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
